Amgen MariTide Obesity Phase 3 Readout Impact on Stock 2026: Why a $415 Base Case Rests on the $100B Weight-Loss Optionality
Amgen (AMGN) trades at a 15.6x forward P/E while its base business grows double digits and MariTide gives a near-free obesity option. Base case $415, Buy.